Consultants

Dr. Alison Uriel is Senior Specialty Doctor in Infectious Diseases and Tropical Medicine at North Manchester General Hospital, part of the Manchester University NHS Foundation Trust (MFT). She serves as the Research Lead in Infectious Diseases at the hospital and holds the position of Specialty Clinical Lead for Infection Research at the National Institute for Health and Care Research (NIHR) Clinical Research Network Greater Manchester.

Professional Background and Contributions:

• Clinical Research Leadership: Dr. Uriel has played a pivotal role in advancing clinical research within the field of infectious diseases. She has been instrumental in mentoring emerging researchers, such as Dr. Irvine Mangawa, through initiatives like the NIHR’s Associate Principal Investigator Scheme. rdn.nihr.ac.uk

• Innovative HIV Treatment Trials: As the Principal Investigator at North Manchester General Hospital, Dr. Uriel leads the RIO trial, which explores the efficacy of long-acting immune-based treatments for HIV. This study investigates the potential of broadly neutralising monoclonal antibodies to maintain viral suppression without the need for daily antiretroviral therapy. research.cmft.nhs.uk

• COVID-19 Research Initiatives: Dr. Uriel is at the forefront of evaluating next-generation COVID-19 prophylactic treatments. She leads the SUPERNOVA study at MFT, assessing the safety and effectiveness of long-acting antibodies designed to provide extended protection against COVID-19, particularly for individuals with compromised immune systems. research.cmft.nhs.uk

Educational and Professional Development:

• Mentorship and Training: Dr. Uriel’s commitment to fostering the next generation of clinical researchers is evident through her mentorship roles. She has guided healthcare professionals in developing leadership skills and gaining practical research experience, thereby enhancing the capacity for high-quality clinical research within the NHS. rdn.nihr.ac.uk

Contribution to research

• Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial. Haidar G, Thomas S, Loubet P, Baker RI, Benfield T, Boonyaratanakornkit J, Kiertiburanakul S, Kim AHJ, Longbrake EE, Molina JM, Paredes R, Tucker D, Uriel A, Weinmann-Menke J, Aksyuk AA, Clegg LE, Currie A, Yang H, Flyrin K, Gibbs M, Shroff M, Perez JL, Chang LJ, Cohen TS; SUPERNOVA study group.Lancet Infect Dis. 2025 Feb 24:S1473-3099(24)00804-1. doi: 10.1016/S1473-3099(24)00804-1.
• Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort. Trottier B, Yang CJ, Watanabe D, Marchetti G, Elbirt D, De Barra E, Gündüz A, Lee SH, Vogelmann R, Robineau O, Choy CY, Berrevoets M, Uriel A, Thorpe D, Heinzkill M, Marongiu A, Ramroth J, D’Amato L, Mallolas J.HIV Res Clin Pract. 2025 Dec;26(1):2456890. doi: 10.1080/25787489.2025.2456890.
• Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration.
  Pantazis N, Sabin CA, Grabar S, Van der Valk M, Jarrin I, van Sighem A, Meyer L, Carlander C, Gill J, Volny Anne A, Spire B, Tariq S, Burns F, Costagliola D, Ruiz-Burga E, Touloumi G, Porter K; CASCADE Collaboration. Lancet HIV. 2024 Oct;11(10):e660-e669. doi: 10.1016/S2352-3018(24)00183-8.

Dr. Uriel’s dedication to clinical excellence, research innovation, and mentorship significantly contributes to advancements in infectious disease treatment and prevention, both within the Greater Manchester region and beyond.

GMC: 3190463